Over the last two decades epidermal growth factor receptor (EGFR) kinase has become an important target to treat non-small cell lung cancer (NSCLC). Currently, three generations of EGFR kinase-targeted small molecule drugs have been FDA approved. They nominally produce a response at the start of treatment and lead to a substantial survival benefit for patients. However, long-term treatment results in acquired drug resistance and further vulnerability to NSCLC. Therefore, novel EGFR kinase inhibitors that specially overcome acquired mutations are urgently needed. To this end, we carried out a comprehensive study of different EGFR kinase mutants using a structural systems pharmacology strategy. Our analysis shows that both wild-type and mutated structures exhibit multiple conformational states that have not been observed in solved crystal structures. We show that this conformational flexibility accommodates diverse types of ligands with multiple types of binding modes. These results provide insights for designing a newgeneration of EGFR kinase inhibitor that combats acquired drug-resistant mutations through a multi-conformation-based drug design strategy.
Introduction
Epidermal growth factor receptor (EGFR) is one of four members of the transmembrane epidermal growth factor receptor family (EGF/ErbB receptor family). It is typically activated by an epidermal growth factor (EGF) that binds to the extracellular domain which protrudes from the cell membrane thereby regulating signaling pathways 1 . Mutation of the EGFR kinase domain leads to higher activity thereby stimulating four major downstream signaling pathways including MAPK/ERK, PLCg/PKC, JAK/STAT and PI3K/AKT which impact transcription and cell cycle progression 2 leading to cancers and inflammatory diseases 3 . Specifically, it has been shown that diverse mutations in the EGFR kinase domain, typically L858R and del746-750, are associated with non-small cell lung cancer (NSCLC) which accounts for about 80% to 85% of all lung cancer cases 4 . Thus, EGFR kinase inhibitors that target these activation mutations are desirable for the treatment of NSCLC. Since 2009, five EGFR kinase inhibitors have been approved by the US Food and Drug Administration (FDA). The first two, Gefitinib and Erlotinib, show efficacy at the start of treatment. However, after about 12 months, drug resistance from an acquired T790M mutation arises 5 . Thus, a second-generation EGFR kinase inhibitor, Afatinib, was developed for the T790M mutation. Because of the limited therapeutic potential of Afatinib 6 , soon after, a thirdgeneration of EGFR kinase inhibitors, Osimertinib and Olmutinib, were developed. Afatinib,
Osimertinib and Olmutinib are all irreversible inhibitors 7 that form a covalent bond with Cys797.
However, the occurrence of an acquired C797S mutation greatly reduces the efficacy of these three covalent drugs. Therefore, to date, this acquired resistance remains a major challenge in the treatment of NSCLC [8] [9] . New EGFR kinase inhibitors that overcome these acquired mutations are needed. Recently, Jia et al. discovered an allosteric EGFR kinase inhibitor (EAI045) 10 , which overcomes both T790M and C797S mutations, and offers a means for treating NSCLC. Further, a 4 few non-covalent ATP-competitive inhibitors that bind to the ATP binding site were rationally designed to overcome acquired resistance [11] [12] [13] [14] [15] . For example, Marcel Günther et al. 14 developed a reversible inhibitor that can inhibit the L858R/T790M/C797S triple mutant. Hwangseo Park et al. 15 also identified a few ATP-competitive inhibitors that overcome the Del746-750/T790M/C797S/ triple mutant. This next-generation allosteric or non-covalent inhibitors demonstrate promising potential and an opportunity to overcome the multiple mutations through designing elaborate inhibitors that match the mutated binding site of the EGFR kinase 16 . These findings prompted us to revisit the EGFR kinase binding site to obtain a detailed understanding of the similarity and differences between the wild-type and mutant EGFR kinases.
Currently, with many available EGFR structures, there is the data-driven opportunity to focus on the EGFR binding site using a structural systems pharmacology strategy [17] [18] [19] [20] . We collected all released structures of the EGFR kinase domain to analyze the overall conformational space of the binding sites as well as the respective kinase-ligand binding modes. We focused on all diverse acquired mutations at the binding sites, exploring the binding site flexibility of EGFR kinase domains with the del746-750/T790M/C797S/ mutation and the L858R/T790M/C797S mutations by using µs-scale molecular dynamics (MD). MD simulation has been successfully applied to study the EGFR conformation space at a computational physiological environment [21] [22] [23] [24] . For example, Park et. al explored the EGFR conformational transition between the inactive and active state to determine the role of gatekeeper mutation on inhibitor selectivity using MD simulations 21 .
Kannan et. al used the combined MD simulation with binding assay data to reveal a mutant specific pocket 24 . Additionally, we scrutinized the binding site features at an atomic level using the function-site interaction fingerprint approach and the volumetric analysis of surface properties.
Our analyses show both wild-type and mutated structures encompass multiple conformational 5 states. Novel conformational state that have not been observed in the solved structures can exist.
The conformational flexibility in the structure accommodates diverse types of ligands with multiple types of binding modes. These results provide us with critical insights into future drug design in treating drug resistant NSCLC and other cancers 25 .
Results

EGFR kinase conformations and mutations
The similarities and differences in EGFR kinase binding sites can be determined by comparing their X-ray structures. We clustered EGFR kinase structures in our dataset into two kinase states, active and inactive and into six classes ( Figure 1a ). In these classes, the side chain of the aspartic acid in the DFG motif points in three different directions: "DFG-In", "DFG-Out", and DFG-
In.
In DFG-
In, the side chain of the aspartic acid points to the roof 26 . Similarly, the C-helix also exhibits significant displacements called "In" and "Out", and the state between them (labeled
Out"). The number of x-ray structures and the representative structure in each class are shown in Figure 1a (a complete clustering of structures is in Table S1 ). Using the representative structure from each class, the major differences in the P-loop, C-helix and DFG motifs are highlighted in Figure 1b . In the active state (Class-1 and Class-2), the DFG motif is in a "DFG-In" state. The Chelix is found in the "In" state (class-1, Figure 1a -b) or has a small displacement referred to as
Out" (Class-2, Figure 1a -b). In the inactive kinase (class-3-6), the DFG motif is found in three directions and the C-helix is found in the "Out" state in all structures. These distinctly different conformations in the binding site of EGFR kinases facilitates the identification of potential sites outside of the conserved ATP-binding site, providing a structural basis to accelerate structurebased drug design through the discovery of novel binding modes.
6
Acquired multi-drug resistance motivates the search for drugs that can target mutated structures.
To begin this process, we catalog the currently available conformations of EGFR kinase domains, both wildtype and mutations, according to the scheme described above (Figure 1c We also marked two important motifs, the R-and C-spine [27] [28] [29] ( Figure S1 ). The catalytic C-spine is assumed highly stable since it is strikingly similar in all six classes of EGFR states. However, the R-spine has different architectures. In Class-1 and 2 at the active state, the R-spine residues are linearly connected. In Class-3 and 4 at the DFG-in/C-helix-out inactive state, the R-spine is partially assembled because the C-helix displacement leads to M766 movement. In the DFG-out inactive state (Class-5 and 6), the R-spine is not assembled because the sidechain of the F856 residue flips to the other side of the DFG peptide. Out" state.
Comparing binding sites among EGFR wildtype and mutants
Thus, the C-helix displacement does not always induce the formation of the back cleft. Secondly, in Class 1-6, the volumetric size of the FP region that binds ATP is similar but the shape is slightly different ( Figure 2 and Table S2 ). formed at BP-II and BP-III. Thus, the cavity of Class-6 has adequate space, not only at the ATPcompetitive site, but also at the allosteric site. This conformational mode may provide the structural basis for the design of diverse type-II and/or type-III EGFR kinase inhibitors [31] [32] . Around the binding site, the flexibility mainly comes from P-loop, the activation loop and C-helix.
From specific detailed comparison of the binding sites, these conformations show a high degree of deviation from the initial crystal x-ray structure (PDB id: 1m17, Class-1, Figure 1a) . Starting from the DFG-In/C-helix-In conformations, the resulting equilibrated structures present different conformations including both the active and inactive states ( Figure 3 ). Among them, the DFG motif exhibits significant displacement from DFG-In to DFG-out, and the C-helix transitions from C-helix-in to C-helix-out. In the trajectory of wild-type structures (Figure 3a) , all six classes of conformation can be sampled. As shown in Figure 3b- in Figure 3c ), which doesn't occur in the EGFR kinase structure dataset. This new conformation ( Figure 4 ) has "DFG-
In/C-helix-out", in which the DFG flipping and C-helix-out displacement are similar to that of Class-4. The difference is that the salt bridge between K745 and E762 occurred in Class-D1 and a hydrogen-bond interaction formed between D855 and K745. This salt bridge and the hydrogen-bond interaction stabilize this dynamic conformation (Figure 4 ). In the Class-D1 state, when C-helix displacement occurs, the sheets consisting of beta-strands 1-5 have a combined displacement outward (Figure 4 ). It will be interesting to screen for novel inhibitors using this new conformation.
We further analyzed the features of the Class-D1 binding pocket. The volume of the binding pocket is 1204 Å 3 ( Figure S7 ), which is slightly larger than that of Class 1-5. We compared the Class-D1 binding site with the other six classes of binding sites. The main difference between
Class-D1 and Class 1-5 is the BP-III region. The main difference from Class 6 is the G-rich-loop region ( Figure S8) . Obviously, the Class-D1 binding pocket has a large sub-pocket at the BP-III region. More specifically, we calculated the similarity between the Class-D1 binding pocket and the other six classes of binding pockets using the volumetric distance 34 (Table S3) , which shows the Class-6 binding site is most similar to Class-D1. Like Class 6, the slightly larger BP-III subpocket is also available in the Class-D1 state. Additionally, to estimate the possible binding mode, we screened the whole kinase structurome, including 3180 kinase-ligand structures 35 , to obtain the most similar binding pocket to the Class-D1 binding pocket. The top complex (Table S4 ) is a JAK1 kinase structure 36 (pdb id: 4e4n), where the ligand (0NL) binds to the pocket by bearing a heterocycloamine scaffold, forming hydrogen bonds with the hinge peptide and a t-butyl carbamate at the G-rich-loop region ( Figure S9 ). We also noted that the distance between the tbutyl and the C-helix is 9.6 Å, which means this BP-III sub-pocket region is not fully utilized. This In summary, the MD simulation reveals more conformational states than those in the released x-ray structure dataset. It is important to analyze the multiple conformational states in the context of the diverse inhibitors that bind to those different conformations. Stated another way, multiple conformations will facilitate novel inhibitor design with a specific SAR. Note, however, that the ligand could also induce a new EGFR kinase conformation with a yet to be discovered binding pocket 37 which points to the need for further structure determination of new ligand-bound complex structures, as well as further computational studies to sample a larger conformation space in the process of drug design in order to obtain the desired SAR 38 . It is well known that the kinase ATP binding site is highly conserved across the whole kinome.
EGFR kinase-ligand binding characterization
In order to achieve the desired selectivity, it is critical to understand the atomic details of kinaseinhibitor interactions 35 . Here, using all released EGFR kinase crystal structures, we analyze and characterize the atomic details of interactions between the ligand and the residues that constitute the EGFR kinase ATP binding site (see Methods and Table S5 for specific PDB structures). Figure   5 shows the contact frequency between specific residues and the bound ligand. Seven types of interatomic interaction are defined based on geometric rules 39 Table S6 ). In cluster-1 (Figure 6b ), the ligand is located at the position of the ATP binding site, where the core binding pocket is highlighted as aforementioned. It is not surprising that most inhibitors fall into this cluster. Typically, there are two or three hydrogen-bond interactions between the ligand and the amino acids located at the hinge 31 . Since the core binding pocket is conserved, this type of inhibitor has a multi-targeted effect across the kinome. For example, the ligand STO (1,2,3,4-tetrahydrogen staurosporine) ( Figure 6b ) is a derivative of the natural product staurosporine 40 , which is known to have broad cross-reactivity 41 . Following the cross reactivity observed, the ligand STO has a specific kinase spectrum that can be targeted. By combining the target spectrum of a given compound, further SAR optimization becomes a valid strategy 26, 42 . By using this strategy, a close analogue of staurosporine (PKC-412, a multi-kinase inhibitor) was approved in April 2017 for treating acute myeloid leukemia (AML), 16 myelodysplastic syndrome (MDS) and advanced systemic mastocytosis [43] [44] [45] . Similar to cluster-1, the cluster-2 interaction patterns also include the ATP-competitive binding mode (Figure 6c ).
However, in this cluster the kinase is in the inactive state and belongs to the Class-6 conformation as described in Figure 1 . In this case the ligand does not have any interaction with the C-helix.
Rather the benzenesulfonyl fluoride ligand fragment presents characteristic interactions, namely the aromatic p-p stacking interaction with the phenylalanine side chain of the DFG motif and the electrostatic interactions with the amino acids on the G-rich loop. In cluster-3 (Figure 6d ), the ligand also presents an ATP-competitive binding mode. However, different from cluster-1, the ligand has a hydrophobic fragment penetrating deeply into the hydrophobic pocket that adjoins the core binding pocket and is located at the back of the kinase binding site 30 . The hydrophobic pocket is often used to achieve the desired selectivity, but mutation of the gatekeeper residues directly affects the efficacy of this type of inhibitor 46 . Cluster-4 ( Figure 6e ) has a non-ATP-competitive binding mode. The ligand is located at the back of the binding site, and occupies the hydrophobic pocket, similar to cluster-3, as well as the allosteric site 47 . In this cluster, the C-helix is displaced outward to the "Out" state and opens up the allosteric site. Thus, the ligand forms interactions with the DFG motif and the C-helix. The allosteric binding mode provides high selectivity overcoming the T790M/C797S mutations 10 . In cluster-5 (Figure 6f ), ligand binding presents two features.
Firstly, the ligand has a phenyl group to bind the hydrophobic pocket that is similar to cluster-3 and cluster-4. Secondly, the tail of the ligand interacts with not only the sidechain of aspartic acid from the DFG motif but also the sidechain of asparagine 842 at b 6 . It is notable that the position of the tail is similar to that in cluster-2, but the binding mode is totally different. Firstly, the tail of the ligand forms an interaction with the aspartic acid of DFG-in in cluster-5, but with the phenylalanine of DFG-out in cluster-2. Secondly, the tail extends towards the A-loop and forms an interaction with Asn842 in cluster-5, but extends towards the P-loop and is in contact with the G-rich loop in cluster-2. In cluster-6, the ligand is an ATP-competitive binder. The furan group of the ligand not only forms very subtle interactions with the hydrophobic pocket but also forms polar interactions with K745, E762 and the DGF motif. As aforementioned, in cluster-4, the C-helix contributes to the binding affinity of the allosteric inhibitor. However, although the inhibitors in cluster-6 are not allosteric inhibitors, the C-helix is in the "C-helix-In" state in close proximity to the oxygen atoms of the furan group thereby forming polar interactions. Thus, the furan group provides unique binding characteristics. In summary, the binding modes of co-crystallized EGFR kinase-ligand complexes are diverse.
They provide the structural basis for mediating inhibitor selectivity, important to keep in mind when designing mutant-sensitive inhibitors.
Conclusions
We have explored the impact of mutations on structural conformation of the EGFR kinase domain for all released crystal x-ray structures. From a detailed structural analysis, we identified six classes of conformation which focus on the flipping of the DFG motif and the displacement of the C-helix. There is no apparent correlation between these mutations and conformation. For example, the common T790M mutation adopted not only the typical DFG-in/C-helix-in conformation but also the DFG-out/C-helix-out. We suggest that the conformations of the EGFR kinase are flexible and can fall into distinct locally stable states. From the perspective of drug design, multi-conformation-based drug screening should be of significant value when targeting EGFR kinases.
We also explored the dynamic conformation space occupied by the EGFR kinase using µs-level MD simulation. We not only sampled the multiple different conformations from Class-1 to Class-6 but also found a new conformation mode. In the two acquired mutated kinase systems, we did not sample Class-5 and Class-6 conformations; advanced sampling technologies are needed.
Less of an issue perhaps since Class-5 and Class-6 conformations that were obtained from the released ligand-bound structures (Figure 1b) , as well as taking conformational flexibility into account, suggests that the EGFR kinase-ligand binding would induce a specific binding mode and EGFR kinase conformation change. Recently, Sonti et al. 38 reported a similar ligand-induced binding mechanism for Abelson tyrosine kinase (Abl). Abl belongs to the TK group, like the EGFR kinase, and has 60% sequence similarity 48 . Therefore, it is important for EGFR kinase-ligand SAR to take the induced binding mechanism into consideration. This presents a challenge to in silico compound screening for it requires the protein target be considered not as a static structure but as an ensemble of conformations 49 .
Such a change in conformation often results in a change in the binding site. We found that the outward displacement of the C-helix does not always form the BP sub-pockets, (Figure 2b and 2e). 20 We collected all 127 PDB structures of the EGFR kinase domain released through Dec. 2017 from the Protein Data Bank ( www.rcsb.org ) 50 by using the human EGFR UniProt 51 identifier, P00533. There are 20 apo and 107 holo PDB structures in the dataset. The binding sites of all structures were aligned using the SMAP software [52] [53] [54] . We clustered all structures based on the Ca-RMSD of the EGFR N-terminal lobes. The mutations closest to the binding site of each structure was extracted to determine the relationships between the conformation patterns and the mutations.
Method
Dataset of EGFR kinase structures
Differentiating the binding sites
To differentiate the different binding sites, first the given binding sites were pairwise aligned using the SMAP tool 54 . Then, each binding site and each sub-pocket was detected using the Surflex software [55] [56] with default proto parameters. For each sub-pocket, a set of residues bordering the sub-pocket were chose based on Liao's description 30 . Then the volumetric size and shape of each binding site or each sub-pocket was inferred using the volumetric analysis of surface properties (VASP) software 34 , in which all computations were carried out at 0.5 A resolution. Lastly, differentiating the binding sites was determined using the volumetric difference of constructive solid geometry 34 . The similarity was calculated by using the volumetric distance (%,') ,
where, ( ) represents the volume of a given binding site in Å 3 . ( ∩ ) represents the volumetric intersection of ( ) and ( ) for x and y are binding pockets.
Sampling the conformational space using MD
We carried out microsecond-level molecular dynamics (MD) simulation for three systems, the wild-type and two acquired mutated types (L858R/T790M/C797S and del746-750/T790M/C719S). First, the initial structure was prepared from PDB 1m17 with the DFG-in/C-21 helix-in active conformation as the wild-type EGFR kinase domain. Then the corresponding mutated models were built for each system, respectively, using PDB 1m17 as the template and the software modeller 57 . Then each structure was solvated in a cubic box of water molecules with 12Å distance from the solvated molecules and neutralized by adding Cl -and Na + using an ACEMD setup script 58 . Finally, a general short-MD protocol was used for initial minimization and equilibration including 2ps minimization, 100ps for NVT, 1ns for NPT with heavy-atom constraints and 1ns for NPT without any constraints. The next stage was a 1.5 µs equilibration process without the constraint and the last 1000ns of MD trajectories were retained for further analysis.
The MD simulations were carried out using the ACEMD software 58 with the CharMM27 force field for protein and the TIP3P water model for the water molecule 59 . The electrostatic interaction was treated using PME and SHAKE constraints were applied with a 4fs integration time step 60 .
The temperature was kept at 300K using a Langevin bath method and the pressure was maintained at 1 ATM using the Berendsen method. The trajectories were analyzed using the MMTSB toolset 61 .
For the reaction coordinate (RC) of scatter density distribution, we used the salt-bridge distance between K745 and E762 as one RC. Because the flexibility of Cys797 is low as shown in Figure   S4 , we measured the two distances from C797 to D855 and F856, where the difference constitutes another RC.
Function-site interaction fingerprint encoding
Function-site interaction fingerprints (Fs-IFP) are an efficient means to determine functional site binding characteristics and to compare binding sites on a proteome scale as detailed in previous applications 35, [62] [63] . In brief, the Fs-IFP method includes three steps.
Step 1 prepares the dataset.
In this paper, we collected all EGFR kinase-ligand structures as our dataset.
Step 2 aligns all 22 function sites. Here we used the SMAP software [52] [53] [54] with default parameters. Thus, we obtained all aligned residues within the binding pocket.
Step 3 encodes the binding site-ligand interaction.
Based on the aligned residues, we confirmed that every binding site could be described using 39 amino acids that comprised the binding pocket. Then the interactions between every amino acid and the corresponding ligand were encoded using a 7-bit array that represents 7 types of interactions: ((1)van der Waals; (2) aromatic face to face; (3) aromatic edge to face; (4) hydrogen bond (protein as hydrogen bond donor); (5) hydrogen bond (protein as hydrogen bond acceptor); (6) electrostatic interaction (protein positively charged); and (7) electrostatic interaction) 39 . Finally, the kinase-ligand interactions of each complex structure were encoded using a length of 273 bits (7 bits × 39 residues). The encoding was done using IChem software 64 . Further, the similarity of the pairwise Fs-IFPs was calculated using the Tanimoto coefficient (TC). Based on all-against-all pairwise TC similarity, the hierarchical cluster analysis was carried out using R with the single linkage method 65 .
Supporting information
Figure S1-9 illustrate the C-and R-spine analysis, the volume and shape of the binding pockets, the analysis of different MD trajectories, PCA, the Class-D1 binding pocket, the different between the Class-D1 binding site and all the other six classes of EGFR binding sites, and the screened top complex. Table S1-6 describes the EGFR kinase structure dataset, the volume of every sub-pocket conformation, the similarity list, the top similar complex, the index and the pdb id of every kinase structure, and the classes of the binding mode, respectively. The Class-D1 EGFR kinase structure (PDB).
